211 related articles for article (PubMed ID: 33580411)
1. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.
Zhang Z; Song J; Xie C; Pan J; Lu W; Liu M
AAPS J; 2021 Feb; 23(2):29. PubMed ID: 33580411
[TBL] [Abstract][Full Text] [Related]
2. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
Chan JK; Liang SY; Kapp DS; Chan JE; Herzog TJ; Coleman RL; Monk BJ; Richardson MT
Gynecol Oncol; 2020 Dec; 159(3):604-606. PubMed ID: 32994055
[No Abstract] [Full Text] [Related]
3. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
4. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
5. Current treatment landscape and emerging therapies for pancreatic cancer.
Adel N
Am J Manag Care; 2019 Jan; 25(1 Suppl):S3-S10. PubMed ID: 30681819
[TBL] [Abstract][Full Text] [Related]
6. Switch maintenance therapy for advanced bladder cancer: A paradigm shift in 2020.
Chawla NS; Malhotra J; Pal SK
Cancer Treat Res Commun; 2020; 24():100202. PubMed ID: 32805533
[No Abstract] [Full Text] [Related]
7. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
[TBL] [Abstract][Full Text] [Related]
8. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.
Cabebe E; Fisher GA
Expert Opin Investig Drugs; 2007 Apr; 16(4):467-76. PubMed ID: 17371195
[TBL] [Abstract][Full Text] [Related]
10. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
Lakkakula BVKS; Farran B; Lakkakula S; Peela S; Yarla NS; Bramhachari PV; Kamal MA; Saddala MS; Nagaraju GP
Semin Cancer Biol; 2019 Jun; 56():149-167. PubMed ID: 30314681
[TBL] [Abstract][Full Text] [Related]
11. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Goncalves A; Mezni E; Bertucci F
Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of ovarian cancer including immune check point inhibitor.
Kim JY; Cho CH; Song HS
Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
[TBL] [Abstract][Full Text] [Related]
13. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
14. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors in Pancreatic Cancer.
Brown TJ; Reiss KA
Cancer J; 2021 Nov-Dec 01; 27(6):465-475. PubMed ID: 34904809
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
Parchment RE; Doroshow JH
Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
[TBL] [Abstract][Full Text] [Related]
17. State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?
Balsano R; Tommasi C; Garajova I
Anticancer Res; 2019 Jul; 39(7):3405-3412. PubMed ID: 31262862
[TBL] [Abstract][Full Text] [Related]
18. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
20. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Rizzo A; Ricci AD; Brandi G
Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
